Smith Thornton Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.38M Hold
1,189
– – 0.6% 45
2026
Q2
$1.4M Buy
1,189
+288
+32% +$294K 0.62% 45
2026
Q1
$828K Buy
901
+1
+0.1% +$1.01K 0.42% 60
2025
Q4
$968K Sell
900
-6
-0.7% -$5.74K 0.49% 54
2025
Q3
$692K Buy
906
+5
+0.6% +$3.72K 0.36% 67
2025
Q2
$703K Buy
901
+70
+8% +$54.4K 0.4% 62
2025
Q1
$686K Buy
831
+37
+5% +$30.8K 0.43% 60
2024
Q4
$613K Buy
794
+335
+73% +$277K 0.39% 69
2024
Q3
$407K Buy
459
+3
+0.7% +$2.7K 0.27% 92
2024
Q2
$413K Buy
+456
New +$365K 0.3% 84

Other funds holding LLY

Smith Thornton Advisors's LLY Position: Q3 2026 in Review

Smith Thornton Advisors held its Eli Lilly (LLY) position steady in Q3 2026 at 1,189 shares worth $1.38M. The position accounts for 0.6% of the portfolio, ranked #45.

Smith Thornton Advisors first reported a position in LLY in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.4M in Q2 2026. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Smith Thornton Advisors held 1,189 shares of Eli Lilly worth $1.38M as of Q3 2026.
  • Smith Thornton Advisors left its Eli Lilly share count unchanged in Q3 2026.
  • Eli Lilly made up 0.6% of Smith Thornton Advisors's portfolio in Q3 2026, its #45 holding.
  • Smith Thornton Advisors first reported a position in Eli Lilly in Q2 2024 and has held it in 10 quarters since.
  • Smith Thornton Advisors's Eli Lilly position peaked at $1.4M in Q2 2026.
  • 2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Smith Thornton Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.